S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis

Canopy Growth (CGC) Stock Forecast & Price Target

$7.93
+0.10 (+1.28%)
(As of 04/19/2024 ET)

Canopy Growth Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Reduce
Based on 4 Analyst Ratings

Analysts' Consensus Price Target

$4.87
-38.63% Downside
High Forecast$6.60
Average Forecast$4.87
Low Forecast$3.00
TypeCurrent Forecast
4/22/23 to 4/21/24
1 Month Ago
3/23/23 to 3/22/24
3 Months Ago
1/22/23 to 1/22/24
1 Year Ago
4/22/22 to 4/22/23
Consensus Rating
Reduce
Reduce
Hold
Reduce
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
1 Buy rating(s)
3 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
5 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
5 Sell rating(s)
Consensus Price Target$4.87$4.87$16.20$37.90
Predicted Upside-38.63% Downside-34.17% Downside-10.14% Downside10.05% Upside
Get Canopy Growth Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CGC and its competitors with MarketBeat's FREE daily newsletter.

CGC Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CGC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Canopy Growth Stock vs. The Competition

TypeCanopy GrowthMedical CompaniesS&P 500
Consensus Rating Score
1.50
2.68
2.49
Consensus RatingReduceModerate BuyHold
Predicted Upside-38.63% Downside1,023.44% Upside11.96% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/12/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderperform$5.00 ➝ $3.00-21.47%
1/31/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform$5.00+3.31%
9/15/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderperform ➝ Underperform$5.60 ➝ $6.60-51.18%
5/1/2023BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 11:33 AM ET.

CGC Price Target - Frequently Asked Questions

What is Canopy Growth's consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Canopy Growth stock is Reduce based on the current 2 sell ratings and 2 hold ratings for CGC. The average twelve-month price prediction for Canopy Growth is $4.87 with a high price target of $6.60 and a low price target of $3.00. Learn more on CGC's analyst rating history.

Do Wall Street analysts like Canopy Growth more than its competitors?

Analysts like Canopy Growth less than other Medical companies. The consensus rating for Canopy Growth is Reduce while the average consensus rating for medical companies is Moderate Buy. Learn more on how CGC compares to other companies.

Does Canopy Growth's stock price have much downside?

According to analysts, Canopy Growth's stock has a predicted downside of -34.17% based on their 12-month stock forecasts.

What analysts cover Canopy Growth?

Canopy Growth has been rated by Piper Sandler, and Sanford C. Bernstein in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:CGC) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners